Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review

Hyperfractionated accelerated radiotherapy (hart) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (nsclc): results of a phase ii study for patients ineligible for combination radiochemotherapy

“…Dose-escalation via three-dimensional (3D) planning and conformal radiotherapy is an important development, and is currently being investigated (6 -8). Combination chemotherapy and radiotherapy have been extensively studied with a large number of drug associations and radiochemotherapy schedules (9,10). Meta-analyses have concluded that results favor combined cisplatin-based chemotherapy; however, the gain in terms of 3-and 5-year survival is quite modest (11,12).…”